2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery
This guideline cites 6 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2024
- Source
- Thompson A, Fleischmann KE, et al. Circulation. 2024;150(19):e351–e442.doi 10.1161/CIR.0000000000001285
The 2024 guideline replaces the 2014 document and lands close to the ESC 2022 position: a stepwise algorithm driven by surgical risk, functional capacity and a validated risk index, with testing reserved for cases in which the result would change management. Like the ESC it recognises myocardial injury after noncardiac surgery (MINS) as a diagnosis, but it is more cautious about routine perioperative troponin surveillance and does not endorse it as broadly. It also gives explicit guidance on the perioperative handling of GLP-1 receptor agonists and SGLT2 inhibitors — drugs the European document predates. Much of the evidence base is negative, and the trials that closed questions are grouped below.
Perioperative beta-blockade1
- 2008POISE CoreCardiology · Cardioprotection · Beta-blockadeIn 8,351 patients with or at risk of atherosclerotic disease undergoing non-cardiac surgery, extended-release metoprolol started hours before surgery reduced cardiovascular death, non-fatal myocardial infarction or non-fatal cardiac arrest at 30 days but increased death and stroke compared with placebo.HR 0.8495% CI 0.70-0.99Read →
Perioperative antithrombotic & antifibrinolytic therapy3
- 2022POISE-3Cardiology · Cardioprotection · Antifibrinolytic therapyIn 9,535 patients undergoing non-cardiac surgery at risk of bleeding and cardiovascular events, intravenous tranexamic acid reduced life-threatening, major or critical-organ bleeding at 30 days, but non-inferiority for the cardiovascular safety composite was not established compared with placebo.HR 0.7695% CI 0.67-0.87Read →
- 2018MANAGECardiology · Cardioprotection · Antithrombotic therapyIn 1,754 patients with myocardial injury after non-cardiac surgery, dabigatran 110 mg twice daily reduced major vascular complications without a significant increase in major bleeding compared with placebo.HR 0.7295% CI 0.55-0.93Read →
- 2014POISE-2 CoreCardiology · Cardioprotection · Aspirin and clonidineIn 10,010 patients at risk of vascular complications undergoing non-cardiac surgery, neither low-dose aspirin nor clonidine started just before surgery reduced death or non-fatal myocardial infarction at 30 days; aspirin increased major bleeding and clonidine increased hypotension, compared with placebo.Read →
Preoperative revascularisation2
- 2020ISCHEMIA CoreCardiology · Coronary · RevascularisationIn 5,179 patients with stable CAD and moderate-to-severe ischaemia, an initial invasive strategy did not reduce CV death, MI, hospitalisation for unstable angina, HF or resuscitated arrest compared with an initial conservative strategy.HR 0.93Read →
- 2004CARPCardiology · Cardioprotection · Preoperative revascularisationIn 510 patients with stable coronary artery disease scheduled for elective major vascular surgery, prophylactic coronary revascularisation before surgery did not reduce long-term all-cause mortality or postoperative myocardial infarction compared with no preoperative revascularisation.RR 0.9895% CI 0.70-1.37Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2012VISION
The cohort that established postoperative troponin elevation as an independent predictor of death — the origin of the MINS concept.
- 2009DECREASE family
Withdrawn after scientific misconduct; its retraction is why perioperative beta-blocker evidence rests on POISE alone.
- 2015BRIDGE
Bridging anticoagulation before surgery in atrial fibrillation was unnecessary and caused bleeding.
- 2019PAUSE
A standardised, no-bridging interruption protocol for direct oral anticoagulants around surgery.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.